Resistance to Ibrutinib

Publication
Article
Special ReportsHematologic Malignancies
Volume 1
Issue 1

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

View more about the treatment of chronic lymphocytic leukemia > >

Articles in this issue
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AML
In the Pipeline: Potential New Treatments for AML
In the Pipeline: Potential New Treatments for AML
Epidemiology in B-Cell Malignancies
Epidemiology in B-Cell Malignancies
Pathogenesis of Follicular Lymphoma
Pathogenesis of Follicular Lymphoma
Resistance to Ibrutinib
Resistance to Ibrutinib
IPI-145 and ABT-199 for Lymphoid Malignancies
IPI-145 and ABT-199 for Lymphoid Malignancies
BCL-2 Inhibitor Combo May Offer Remissions in CLL
BCL-2 Inhibitor Combo May Offer Remissions in CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL
In Practice: Challenges in Treating Patients With Relapsed or Refractory CLL

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Outcomes With Luspatercept Not Affected by Mutational Profile in MDS

Outcomes With Luspatercept Not Affected by Mutational Profile in MDS

Targeted Oncology Staff
July 7th 2025
Article

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

TROP-2 Inhibitors Are Explored in Breast Cancer

TROP-2 Inhibitors Are Explored in Breast Cancer

Tony Berberabe, MPH
June 28th 2025
Article

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert insights and groundbreaking research.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Bladder-Sparing Approaches Gaining Ground in NMIBC

Bladder-Sparing Approaches Gaining Ground in NMIBC

Tony Berberabe, MPH
June 27th 2025
Article

Innovative treatments for non–muscle-invasive bladder cancer emerge, focusing on bladder preservation and improved outcomes with novel therapies and active surveillance strategies.

Read More

Targeted CLL Agents Reshape Treatment Paradigm, But Unmet Needs Remain

Targeted CLL Agents Reshape Treatment Paradigm, But Unmet Needs Remain

Jason M. Broderick
Published: June 26th 2025 | Updated: June 27th 2025
Article

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line or later CLL treatment.

Read More